Publications & Presentations

P2B001 Publications

1. Olanow CW et al. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941.
2. Hauser RA et al. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2.
3. Olanow WG. Efficacy and safety of P2B001 in the management of early Parkinson’s disease. Results from a phase 3, randomized, double-blind, double-dummy controlled trial. Presented at: AAN Annual Meeting; April 2-7, 2022; Seattle, WA, and virtual. Abstract 011.

   Review

4. Olanow WG. P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial. Presented at: MDS Annual Meeting; Sept 15-18, 2022; Madrid, Spain and virtual. Abstract 750.

   Review

P2B001 Presentations

1. Patient outcomes with P2B001: Phase 3 top-line results.
   Prof. C Warren Olanow

   Review

2. Why we need more treatment options for early-stage Parkinson’s disease?
   Prof. Robert A. Hauser

   Review